Streetbeat News

Stock Prices

ARWR

Arrowhead Pharmaceuticals shares rose following positive results from the Phase 3 PALISADE study of plozasiran for familial chylomicronemia syndrome.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:56 am

PM

Philip Morris International (PMI) reaffirms its 2024 full-year forecast for adjusted EPS of $6.33 to $6.45, with an estimated $6.40. The forecast indicates a currency-neutral increase of 11% to 13% compared to 2023.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:55 am

PWUP

Trading for an unspecified asset was halted at 7:55 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the asset's price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:55 am

PWUPW

Trading for PWUPW has been halted as of 7:55:00 a.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:55 am

PWUPU

Trading for PWUPU has been halted as of 7:55:00 a.m. ET due to pending news. Investors should stay alert for updates that could impact the stock's price.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:55 am

X

United States Steel shares declined following Vice President Harris's opposition to the company's sale to Nippon Steel.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:54 am

SHLS

Shoals Technologies' shares rose following a favorable legal ruling from the U.S. ITC in its patent infringement case against Voltage, LLC and a related foreign entity.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:51 am

U

Unity Software shares rose following an upgrade by Morgan Stanley from Equal-Weight to Overweight.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:48 am

PCVX

Vaxcyte shares rise as the company advances VAX-31 to a Phase 3 program after positive Phase 1/2 results.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:46 am

DYN

Dyne Therapeutics shares are trading lower following the announcement of new clinical data from its Phase 1/2 DELIVER trial of DYNE-251. The trial showed unprecedented dystrophin expression and functional improvement in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:44 am